• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Management of drug resistantTB in patients with HIV co-infection
【24h】

Management of drug resistantTB in patients with HIV co-infection

机译：HIV合并感染患者的耐药结核病管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) are major public health concerns worldwide. Their association with HIV/AIDS infection has contributed to the slowing down of TB incidence decline over the last two decades, therefore representing one of the most important barriers to reach TB elimination. Areas covered: The aim of this manuscript is to critically review the recent scientific evidence on the management of drug-resistant TB (essentially MDR- and XDR-TB) in subjects coinfected with HIV, focusing on the two new recently-approved anti-TB drugs delamanid and bedaquiline. The medical search-engine PubMed was used, selecting the time-period January 2013 - February 2015, and using the following Keywords: drug-resistant TB, multidrug resistant TB (or MDR-TB), extensively drug-resistant TB (or XDR-TB), delamanid and bedaquiline. Expert opinion: The TB/HIV co-epidemic can be faced by implementing the 12 TB/HIV collaborative activities recommended by the World Health Organization. They are focused on the systematic screening of individuals to detect the Mycobacterium tuberculosis infection in HIV-positives, as well as HIV infection in TB patients in order to ensure a rapid initiation of the anti-retroviral therapy (ART). The clinical and public health management of HIV-positive individuals with MDR-TB is complex and expensive, given the cost of second line anti-TB drugs (including the new drugs, delamanid and bedaquiline) and ART. Political commitment and more investment to identify shorter, cheaper and effective anti-TB and HIV regimens as well as better diagnostics and, hopefully, a vaccine will contribute to boost the efforts to eliminate TB.
机译：简介：耐多药和广泛耐药结核病（MDR和XDR-TB）是全球主要的公共卫生问题。在过去的二十年中，它们与艾滋病毒/艾滋病感染的关系促使结核病发病率下降的速度减缓，因此，这是消除结核病的最重要障碍之一。涵盖的领域：本手稿的目的是严格审查有关合并感染HIV的受试者中耐药结核病（主要是MDR和XDR-TB）的管理的最新科学证据，重点是最近批准的两种新的抗结核病药物地拉曼胺和苯达喹啉。使用医学搜索引擎PubMed，选择时间范围为2013年1月至2015年2月，并使用以下关键字：耐药结核病，多药耐药结核病（或MDR-TB），广泛耐药结核病（或XDR- TB），德拉曼尼德和苯达喹啉。专家意见：实施世界卫生组织建议的12项结核/艾滋病合作活动可以面对结核/艾滋病的共同流行。他们专注于系统地筛选个体以检测HIV阳性的结核分枝杆菌感染以及TB患者的HIV感染，以确保快速开始抗逆转录病毒疗法（ART）。鉴于二线抗结核药物（包括新药，德拉曼尼和苯达喹啉）和抗逆转录病毒疗法的费用，对具有耐多药结核病的HIV阳性个体的临床和公共卫生管理既复杂又昂贵。政治上的承诺和更多的投资，以确定更短，更便宜，更有效的抗结核病和艾滋病毒治疗方案以及更好的诊断方法，希望疫苗将有助于促进消除结核病的努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号